The IRMA Community
Newsletters
Research IRM
Click a keyword to search titles using our InfoSci-OnDemand powered search:
|
Molecular-Docking-Based Drug Design and Discovery: Rational Drug Design for the Subtype Selective GPCR Ligands
Abstract
Currently 30-50% of drug targets are G Protein-Coupled Receptors (GPCRs). However, the clinical useful drugs for targeting GPCR have been limited by the lack of subtype selectivity or efficacy, leading to undesirable side effects. To develop subtype-selective GPCR ligands with desired molecular properties, better understanding is needed of the pharmacophore elements and of the binding mechanism required for subtype selectivity. To illustrate these issues, we describe here three successful applications to understand the binding mechanism associated with subtype selectivity: 5-HT2B (5-Hydroxytryptamine, 5-HT) serotonin receptor (HT2BR), H3 histamine receptor (H3HR) and A3 adenosine receptor (A3AR). The understanding of structure-function relationships among individual types and subtypes of GPCRs gained from such computational predictions combined with experimental validation and testing is expected the development of new highly selective and effective ligands to address such diseases while minimizing side-effects.
Related Content
|
Abul Kalam Azad, Mohamad Dayoob, Fatema Tuz Zohera.
© 2024.
21 pages.
|
|
W. H. P. A. D. Perera, Mithuni N. Senadeera, Dinusha N. Udukala.
© 2024.
26 pages.
|
|
Thi Van Anh Nguyen, Trang Nguyen Ngoc, Thanh Tung Bui.
© 2024.
43 pages.
|
|
Abul Kalam Azad, Mallari Praveen, Wan Mohd Azizi Bin Wan Sulaiman.
© 2024.
31 pages.
|
|
Bancha Yingngam.
© 2024.
43 pages.
|
|
Babi Lakkoju, Swapna Asuthkar, Gundla Rambabu, Kolli Balakrishna.
© 2024.
20 pages.
|
|
Arthi Gunasekaran, Trisha Sathya, Vijaya Anand Arumugam, Balamuralikrishnan Balasubramanian, Asirvatham Alwin Robert, Arun Meyyazhagan.
© 2024.
31 pages.
|
|
|